ZINPLAVA
(Bezlotoxumab)ApprovedMonoclonal antibody
Merck & Co.ZINPLAVA is one of 49 biologic programs targeting Clostridioides difficile Infection. It is currently in Approved.
3
Indications
11
Total Trials
0
Active Trials
48
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Mortality
#DrugCompanyPhaseTrials
1Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lovenox
SanofiApproved
Aldactone
PfizerApproved
Coly-Mycin M
PParkedale
Approved
Merrem
BB. Braun Medical Inc.
Approved
Zocor
OOrganon and Co
Approved
Venofer
AAmerican Regent, Inc.
Approved
Mounjaro
Eli LillyPhase 3
ZINPLAVA
Merck & Co.Approved
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clostridium Difficile Infection4 trials
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
Terminated·—·Phase 4·NCT04626947·19 enrolled
Show 1 more trial
Clostridioides difficile Infection2 trials
Hospitalized Patients1 trial
Mortality1 trial
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
Terminated·—·Phase 4·NCT03756454·5 enrolled
2 more indications
MPA1 trial
ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI
Completed·—·Phase 2·NCT03829475·61 enrolled
Regulatory
FDA Approval Timeline[4]
Oct 21, 2016
ZINPLAVA
BLA BLA761046
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bezlotoxumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Approved[1]
- Company